Investor Presentaiton
...along with Accretive Acquisitions...
Successful Track Record of Integrating Acquisitions
Acquisitions
Target Country
Transaction Date
NOVA
PHARMACEUTICALS
Australia
March 24, 2006
Bell's Healthcare
United Kingdom
December 31, 2007
Relon Chem
United Kingdom
August 27, 2008
5.7
Time-Cap Labs, Inc.
United States
June 30, 2015
2.9
Sales increase from
43.9
4.3
acquisition to FY21
(x)
Rationale
To leverage Nova's research
capabilities
To strengthen UK market
presence
To establish UK front end presence
To establish US front end presence
■ To establish ANZ front end
presence
To enter OTC segment
Fund Raise
PE-UTI Ventures,
FCCB
QIP
Spring Hill Bioventures
Deal value
300 mn
USD 50 mn
USD 21 mn
Transaction Date
Feb 2003
Nov 2005
End use
Startup Funding
Expansion
Mar 2015
Time-Cap acquisition
funding
Preferential allotment-
Orbimed, Promoters
3,720 mn
July 2021
Utilise Orbimed's resources & expertise to
accelerate Marksans endeavour of
becoming a fully integrated global company
©2021 - Marksans Pharma Limited, All Rights Reserved.
17View entire presentation